Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors

被引：0
|
作者：
Wang, X.
Syed, S.
Masson, E.
Walters, I. B.
Roy, A.
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3095
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE I RESULTS.
    Parikh, A.
    Menon, R.
    Afar, D.
    Naumovski, L.
    Friedel, A.
    Kasichayanula, S.
    Mensing, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S67 - S67
  • [22] DASATINIB PHARMACOKINETICS AND EXPOSURE-RESPONSE (E-R): RELATIONSHIPS TO EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Nicaise, C.
    Wang, X.
    Roy, A.
    Pfister, M.
    Chen, T. T.
    Bleickardt, E.
    Hochhaus, A.
    Shah, N. P.
    Nicolini, F. E.
    Clark, R. E.
    Saglio, G.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 227 - 227
  • [23] Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Feng, Yan
    Wang, Xiaoning
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S67 - S67
  • [24] TIME DEPENDENT PK OF PEMBROLIZUMAB AND IMPLICATION IN EXPOSURE-RESPONSE (E-R) ANALYSIS.
    Li, H.
    Yu, J.
    Liu, C.
    Wang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S73 - S73
  • [25] PREDICTABLE PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD), AND EXPOSURE-RESPONSE (E-R) OF BELATACEPT AVOID THE NEED OF THERAPEUTIC DRUG MONITORING (TDM)
    Shen, Jinshan
    Zhou, Zexun
    Townsend, Robert
    Kaul, Sanjeev
    TRANSPLANT INTERNATIONAL, 2011, 24 : 254 - 254
  • [26] Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
    Fudio, Salvador
    Tabernero, Josep
    Subbiah, Vivek
    Chawla, Sant P.
    Moreno, Victor
    Longo, Federico
    Lopez, Rafael
    Anton, Antonio
    Trigo, Jose Manuel
    Shapiro, Geoffrey
    Jeong, Woondong
    Villalobos, Victor Manuel
    Lubomirov, Rubin
    Fernandez-Teruel, Carlos
    Alfaro, Vicente
    Boni, Valentina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 113 - 124
  • [27] PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF ABBV-321, AN EGFR-TARGETING ADC, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Huang, K.
    Boehm, N.
    Gan, H.
    Car-Neiro, B.
    Robinson, R.
    Aristide, M. Neagu
    Atluri, H.
    Menon, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S25 - S25
  • [28] Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Analyses Confirm the Effectiveness of Lanadelumab in Patients 2 to <12 Years Old With Hereditary Angioedema (HAE)
    Ahmed, Mariam
    Wang, Yi
    Yu, Ming
    Marier, Jean-Francois
    Bhattacharya, Indranil
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB130 - AB130
  • [29] Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)
    Lu, Ming
    Deng, Chenhui
    Xiong, Yifeng
    Wang, Hengbang
    Xu, Ping
    Men, Lichuang
    Xie, Tanhong
    Jiang, Qian
    Chen, Zi
    Niu, Qian
    Liu, Ping
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2020, 136
  • [30] Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
    Gong, Xiaohua
    Akil, Ayman
    Ndi, Andre
    Ji, Tao
    Liu, Xiang
    Lovern, Mark
    Chen, Xuejun
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1784 - 1794
12345